Over-the-Counter (OTC) CGM Options
In 2024, the FDA cleared the first OTC CGMs, led by Dexcom's Stelo and Abbott's Lingo and Libre Rio, democratizing access to metabolic data.
Reviewed by CGM AFIA Editorial Team. Last reviewed: 2026-01-24.
Author: CGM AFIA Editorial Team
A New Era in Metabolic Health
In 2024, the FDA cleared the first Over-the-Counter (OTC) Continuous Glucose Monitors, fundamentally changing the metabolic health landscape.
Market Leaders
Dexcom Stelo
- 15-day wear time
- Targeted at non-insulin Type 2 diabetes
- No prescription required
Abbott Lingo
- Wellness and coaching focus
- Designed for metabolic health optimization
- Consumer-friendly app experience
Abbott Libre Rio
- Type 2 diabetes management
- Over-the-counter availability
- Similar technology to prescription Libre
Key Differences from Prescription CGMs
The primary technical distinctions between OTC and Rx units:
| Feature | Prescription CGM | OTC CGM | |---------|-----------------|---------| | Hypoglycemia alarms | Critical alerts | Removed | | Pump integration | AID compatible | Not available | | Intended use | Insulin dosing | Trend awareness | | Data sampling | High frequency | Sufficient for trends |
Who Benefits?
OTC CGMs democratize access to metabolic data for:
- Pre-diabetics monitoring glucose response
- "Biohackers" optimizing metabolic health
- Non-insulin Type 2 diabetics
Economic Model
OTC CGMs rely on a cash-pay model and are generally not covered by insurance.